Therapy | Low-grade HCMV-IEA (n = 19) | High-grade HCMV-IEA (n = 61) | Low-grade HCMV-LA (n = 33) | High-grade HCMV-LA (n = 47) |
---|---|---|---|---|
Gamma knife | 7 (37%) | 10 (16.4%) | 10 (30%) | 7 (15%) |
RT + adjuvant chemotherapy | 7 (37%) | 28 (46%) | 14 (42%) | 21 (45%) |
Adjuvant chemotherapy | 2 (11%) | 7 (11%) | 2 (6%) | 7 (15%) |
RT + Temozolomide | 2 (11%) | 8 (13%) | 4 (12%) | 6 (13%) |
RT | 1 (5.3%) | 3 (5%) | 1 (3%) | 3 (6%) |
RT + Lumostin | 0 (0%) | 1 (2%) | 0 (0%) | 1 (2%) |
RT + IRESSA | 0 (0%) | 2 (3%) | 2 (6%) | 0 (0%) |
Cortisone | 0 (0%) | 1 (2%) | 1 (3%) | 0 (0%) |
Palliative therapy | 0 (0%) | 4 (7%) | 1 (3%) | 3 (6%) |